Rocaltrol is a synthetic form of vitamin d3 used in clinical practice. Its pharmacological action involves binding to vitamin d receptors in target cells. This binding regulates the expression of genes that increase calcium absorption in the intestines. By enhancing intestinal calcium uptake, the medication helps maintain adequate serum calcium levels. The drug also promotes bone mineralization and modulates the activity of osteoblasts and osteoclasts. Through these mechanisms Rocaltrol provides therapeutic benefit for patients with lipid malabsorption and secondary hyperparathyroidism.

Rocaltrol is a synthetic analogue of vitamin d that is administered orally. It is prescribed to treat secondary hyperparathyroidism in patients with chronic kidney disease. The medication works by binding to vitamin d receptors in target cells. Activation of these receptors modulates calcium and phosphate homeostasis. This interaction leads to increased intestinal absorption of calcium and phosphate. The resultant changes reduce parathyroid hormone secretion and promote bone mineralization. Rocaltrol's pharmacodynamic action mimics the physiological effects of natural vitamin d metabolites. The drug's chemical structure enhances its stability and receptor affinity compared with endogenous hormones.

Common side effects often include mild headache. A sensation of heaviness in the limbs may occur. Occasional nausea is reported. Brief fatigue is also noted. Some individuals experience temporary dizziness. A slight rise in temperature may be observed.

Headache is frequently reported among users. Nausea occurs in a noticeable number of cases. Fatigue is commonly described in patient records. Dizziness appears regularly in symptom logs. Mild muscle aches are often noted. A dry cough is among the typical complaints.